JP2008532949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008532949A5 JP2008532949A5 JP2007558266A JP2007558266A JP2008532949A5 JP 2008532949 A5 JP2008532949 A5 JP 2008532949A5 JP 2007558266 A JP2007558266 A JP 2007558266A JP 2007558266 A JP2007558266 A JP 2007558266A JP 2008532949 A5 JP2008532949 A5 JP 2008532949A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- humanized
- residues
- hla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 26
- 102000004965 antibodies Human genes 0.000 claims 16
- 108090001123 antibodies Proteins 0.000 claims 16
- 239000000427 antigen Substances 0.000 claims 9
- 102000038129 antigens Human genes 0.000 claims 9
- 108091007172 antigens Proteins 0.000 claims 9
- 102100002977 CDR1 Human genes 0.000 claims 4
- 101700073818 CDR1 Proteins 0.000 claims 4
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 4
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 150000001768 cations Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- 229940121354 immunomodulators Drugs 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 102000005614 monoclonal antibodies Human genes 0.000 claims 2
- 108010045030 monoclonal antibodies Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 1
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims 1
- 206010059512 Apoptosis Diseases 0.000 claims 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 claims 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 claims 1
- 229940039227 DIAGNOSTIC AGENTS Drugs 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 229940088597 Hormone Drugs 0.000 claims 1
- 241000406221 Hypostomus robinii Species 0.000 claims 1
- 102000018748 Immunoconjugates Human genes 0.000 claims 1
- 108010027440 Immunoconjugates Proteins 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 1
- 229940074730 OPHTHAMOLOGIC DIAGNOSTIC AGENTS Drugs 0.000 claims 1
- 229920000272 Oligonucleotide Polymers 0.000 claims 1
- JVHROZDXPAUZFK-UHFFFAOYSA-N TETA Chemical compound OC(=O)CN1CCCN(CC(O)=O)CCN(CC(O)=O)CCCN(CC(O)=O)CC1 JVHROZDXPAUZFK-UHFFFAOYSA-N 0.000 claims 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 1
- 231100000765 Toxin Toxicity 0.000 claims 1
- 229910052768 actinide Inorganic materials 0.000 claims 1
- 150000001255 actinides Chemical class 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 229910052785 arsenic Inorganic materials 0.000 claims 1
- 229910052789 astatine Inorganic materials 0.000 claims 1
- 229910052797 bismuth Inorganic materials 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- -1 cytokine Substances 0.000 claims 1
- 230000001419 dependent Effects 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229910052747 lanthanoid Inorganic materials 0.000 claims 1
- 150000002602 lanthanoids Chemical class 0.000 claims 1
- 229910052745 lead Inorganic materials 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrugs Drugs 0.000 claims 1
- 229910052702 rhenium Inorganic materials 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 229910052713 technetium Inorganic materials 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
Claims (22)
- ヒト化L243抗体またはその抗原結合断片であって、重鎖可変ドメインの相補性決定領域(CDR)配列CDR1(NYGMN、配列番号4の残基31から35)、CDR2(WINTYTREPTYADDFKG、配列番号4の残基50から66)およびCDR3(DITAVVPTGFDY、配列番号4の残基99から110)と、軽鎖可変ドメインのCDR配列CDR1(RASENIYSNLA、配列番号2の残基24から34)、CDR2(AASNLAD、配列番号2の残基50から56)およびCDR3(QHFWTTPWA、配列番号2の残基89から98)と、ヒト抗体フレームワーク領域と、定常領域とを含み、前記ヒト化L243抗体はHLA−DR + 細胞上のHLA−DRに結合可能する能力を有し、前記ヒト化L243抗体は補体依存性細胞傷害(CDC)または抗体依存性細胞仲介性細胞傷害(ADCC)を誘導することなく前記HLA−DR + 細胞のアポトーシスを誘導する、ヒト化L243抗体またはその抗原結合断片。
- 重鎖可変ドメインおよび軽鎖可変ドメインを含むヒト化L243抗体またはその抗原結合断片であって、前記重鎖可変ドメインのCDR1、CDR2およびCDR3領域、およびフレームワーク残基27、38、46、68および91が、マウスモノクローナル抗体mL243重鎖に由来するものであり、免疫グロブリン重鎖フレームワークドメインの残りの部分が、1つ以上のヒトに由来するものであり、前記軽鎖可変ドメインのCDR1、CDR2およびCDR3領域、およびフレームワーク残基37、39、48および49が、マウスモノクローナル抗体mL243に由来するものであり、免疫軽鎖グロブリンフレームワークドメインの残りの部分が、1つ以上のヒト軽鎖に由来するものであり、前記ヒト化L243抗体が、HLA−DR+細胞上のHLA−DRのうちの少なくとも1つのエピトープに結合できる能力を有する、ヒト化L243抗体またはその抗原結合断片。
- 請求項2に記載の抗体を含む薬学的組成物。
- 1つ以上の腫瘍関連抗原に特異的に結合する1つ以上の追加的結合分子をさらに含み、前記追加的結合分子が、請求項2の組成物の前に、一緒にまたは後に与えられる、請求項3の組成物。
- 1つ以上のペプチド、脂質、重合化担体、ミセル、ナノ粒子、またはそれらの組み合わせ、および1つ以上のエフェクターにコンジュゲートした、請求項2に記載のヒト化L243抗体を含む薬学的組成物。
- 前記組成物が免疫コンジュゲート体である、請求項5に記載の組成物。
- 前記抗体が、1つ以上の脂質にコンジュゲートしている、請求項5に記載の組成物。
- 1つ以上の腫瘍関連抗原に特異的に結合する、1つ以上の追加的結合分子をさらに含む、請求項5に記載の組成物。
- 前記ヒト化L243抗体が、HLA−DRに対する特異性を少なくとも1つ有し、残りの特異性は、1つ以上の腫瘍関連抗原に結合する追加的結合分子に特異的に結合するペプチドに対するものである、請求項5に記載の組成物。
- 前記エフェクターが、治療薬剤または診断薬剤を含む、請求項5に記載の組成物。
- 前記エフェクターが、薬物、プロドラッグ、毒素、酵素、放射性同位体、免疫調節物、サイトカイン、ホルモン、結合分子、オリゴヌクレオチド、干渉RNA、光力学薬剤またはこれらの混合物を含む、請求項5に記載の組成物。
- 前記エフェクターが、FUdR、FUdR−dOまたはこれらの混合物を含む、請求項5に記載の組成物。
- グループII、グループIII、グループIV、グループV、遷移、ランタニドまたはアクチニド金属カチオンまたはこれらの混合物から選択されるカチオンをさらに含む、請求項5に記載の組成物。
- Tc、Re、Bi、Cu、As、Ag、Au、At、Pbまたはこれらの混合物から選択されるカチオンをさらに含む、請求項5に記載の組成物。
- NOTA、DOTA、DTPA、TETA、Tscg−Cys、Taca−Cys、またはこれらの混合物をさらに含む、請求項5に記載の組成物。
- 前記エフェクターが、放射性核種を含む、請求項5に記載の組成物。
- 前記エフェクターが、酵素を含む、請求項5に記載の組成物。
- 前記エフェクターが、免疫調節物を含む、請求項5に記載の組成物。
- 前記エフェクターが、抗血管新生薬剤を含む、請求項5に記載の組成物。
- 前記抗体が、前記抗体が、1つ以上の治療薬剤、診断薬剤またはこれらの混合物にコンジュゲートしている、請求項5に記載の組成物。
- 請求項20の組成物を含むキット。
- 前記ヒト化L243抗体またはその抗原結合断片がIgG4である、請求項2に記載のヒト化L243抗体またはその抗原結合断片。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65769505P | 2005-03-03 | 2005-03-03 | |
US60/657,695 | 2005-03-03 | ||
PCT/US2006/007598 WO2006094192A2 (en) | 2005-03-03 | 2006-03-03 | Humanized l243 antibodies |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008532949A JP2008532949A (ja) | 2008-08-21 |
JP2008532949A5 true JP2008532949A5 (ja) | 2009-04-23 |
JP5214252B2 JP5214252B2 (ja) | 2013-06-19 |
Family
ID=36941857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007558266A Active JP5214252B2 (ja) | 2005-03-03 | 2006-03-03 | ヒト化l243抗体 |
Country Status (10)
Country | Link |
---|---|
US (9) | US7612180B2 (ja) |
EP (2) | EP1853313B1 (ja) |
JP (1) | JP5214252B2 (ja) |
CN (2) | CN103936859A (ja) |
AU (1) | AU2006218454B2 (ja) |
BR (1) | BRPI0607486B8 (ja) |
CA (1) | CA2599734C (ja) |
DK (1) | DK3332808T3 (ja) |
ES (2) | ES2829566T3 (ja) |
WO (1) | WO2006094192A2 (ja) |
Families Citing this family (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7666400B2 (en) | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
US7550143B2 (en) * | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
US7527787B2 (en) * | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
US8491896B2 (en) * | 2002-06-14 | 2013-07-23 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US8658773B2 (en) | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
US9599619B2 (en) | 2002-06-14 | 2017-03-21 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
US8821868B2 (en) | 2002-06-14 | 2014-09-02 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
US7906118B2 (en) | 2005-04-06 | 2011-03-15 | Ibc Pharmaceuticals, Inc. | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
US9005613B2 (en) | 2003-06-16 | 2015-04-14 | Immunomedics, Inc. | Anti-mucin antibodies for early detection and treatment of pancreatic cancer |
US8003111B2 (en) * | 2005-04-06 | 2011-08-23 | Ibc Pharmaceuticals, Inc. | Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo |
US8562988B2 (en) * | 2005-10-19 | 2013-10-22 | Ibc Pharmaceuticals, Inc. | Strategies for improved cancer vaccines |
US9550838B2 (en) | 2004-02-13 | 2017-01-24 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
US20110064754A1 (en) * | 2005-03-03 | 2011-03-17 | Center For Molecular Medicine And Immunology | Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines |
US8491914B2 (en) | 2004-02-13 | 2013-07-23 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for delivery of interference RNA |
US8883160B2 (en) * | 2004-02-13 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
US9481878B2 (en) | 2004-02-13 | 2016-11-01 | Immunomedics, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity |
US7901680B2 (en) * | 2005-10-19 | 2011-03-08 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) vaccines for cancer therapy |
US20110020273A1 (en) * | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
US8034352B2 (en) * | 2005-04-06 | 2011-10-11 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
WO2006107617A2 (en) * | 2005-04-06 | 2006-10-12 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
US8652484B2 (en) | 2004-02-13 | 2014-02-18 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
US8551480B2 (en) | 2004-02-13 | 2013-10-08 | Immunomedics, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity |
US8435539B2 (en) * | 2004-02-13 | 2013-05-07 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
AU2005313971B2 (en) * | 2004-12-08 | 2011-10-13 | Immunomedics, Inc. | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
AU2006218454B2 (en) | 2005-03-03 | 2011-11-17 | Immunomedics, Inc. | Humanized L243 antibodies |
US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
US8158129B2 (en) | 2005-04-06 | 2012-04-17 | Ibc Pharmaceuticals, Inc. | Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo |
US8481041B2 (en) | 2005-04-06 | 2013-07-09 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy |
US8067006B2 (en) | 2005-04-06 | 2011-11-29 | Immunomedics, Inc. | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites |
US8475794B2 (en) | 2005-04-06 | 2013-07-02 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases |
US9931413B2 (en) | 2005-04-06 | 2018-04-03 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
US9623115B2 (en) | 2005-04-06 | 2017-04-18 | Ibc Pharmaceuticals, Inc. | Dock-and-Lock (DNL) Complexes for Disease Therapy |
US8349332B2 (en) | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
US20100226884A1 (en) | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
US9862770B2 (en) | 2005-10-19 | 2018-01-09 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
US8883162B2 (en) | 2005-10-19 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
SG2014013437A (en) | 2005-11-30 | 2014-07-30 | Abbott Lab | Monoclonal antibodies and uses thereof |
RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
CA2675014C (en) * | 2007-01-17 | 2016-03-29 | Immunomedics, Inc. | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
CA2689941C (en) | 2007-06-25 | 2019-10-29 | Esbatech Ag | Methods of modifying antibodies, and modified antibodies with improved functional properties |
DE102007041831A1 (de) * | 2007-09-03 | 2009-03-05 | Siemens Ag | Kontrastmitttel für die Ultraschalluntersuchung der Prostata und Verfahren zur Diagnose von Prostatakrebs |
JPWO2009066655A1 (ja) * | 2007-11-19 | 2011-04-07 | 国立大学法人 鹿児島大学 | アポトーシス誘導能を有するヒト抗体 |
US9272029B2 (en) | 2009-03-26 | 2016-03-01 | Ibc Pharmaceuticals, Inc. | Interferon lambada-antibody complexes |
WO2011091113A2 (en) | 2010-01-22 | 2011-07-28 | Immunomedics, Inc. | Detection of early-stage pancreatic adenocarcinoma |
PL3903829T3 (pl) | 2009-02-13 | 2023-08-14 | Immunomedics, Inc. | Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo |
US20160095939A1 (en) | 2014-10-07 | 2016-04-07 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
WO2010145895A1 (en) * | 2009-05-14 | 2010-12-23 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compositions containing antibodies for treating cd5+ hla-dr+ b or t cell related diseases |
GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
BR112012004274A2 (pt) * | 2009-08-31 | 2016-11-16 | Ibc Pharmaceuticals Inc | composições e métodos de uso de imunotoxinas compreendendo ranpirnase (rap) mostram potente atividade citotóxica |
CN105566498A (zh) * | 2009-08-31 | 2016-05-11 | Ibc药品公司 | 双特异性免疫细胞因子停靠-和-加锁(dnl)复合物及其治疗性用途 |
EP2473186A4 (en) * | 2009-08-31 | 2013-07-10 | Ibc Pharmaceuticals Inc | BIS SPECIFIC IMMUNOZYTOKIN DOCK-AND-LOCK COMPLEXES AND THERAPEUTIC USE THEREOF |
CA2774260C (en) | 2009-09-16 | 2018-10-09 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
CN102573902A (zh) * | 2009-11-05 | 2012-07-11 | 分子医学和免疫学中心 | 用于基于亚单位的痘病毒疫苗的包含痘病毒衍生肽和针对抗原呈递细胞的抗体的免疫偶联物 |
EP2506881B1 (en) | 2009-12-02 | 2024-03-06 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
CA2787054A1 (en) * | 2010-01-11 | 2011-07-14 | Center For Molecular Medicine And Immunology | Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma |
MX360403B (es) | 2010-04-15 | 2018-10-31 | Abbvie Inc | Proteinas de union a amiloide beta. |
US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9518087B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
JP6147665B2 (ja) | 2010-08-14 | 2017-06-14 | アッヴィ・インコーポレイテッド | アミロイドベータ結合タンパク質 |
CA2808211C (en) * | 2010-08-17 | 2018-08-28 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases |
EP2635300A4 (en) * | 2010-11-03 | 2014-04-02 | Ibc Pharmaceuticals Inc | DOCK-AND-LOCK (DNL) CONSTRUCTS FOR THERAPY AGAINST HUMAN IMMUNE WEAKAGE VIRUS (HIV) |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9783601B2 (en) | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
CA2827076A1 (en) | 2011-02-15 | 2012-08-23 | Immumomedics, Inc. | Anti-mucin antibodies for early detection and treatment of pancreatic cancer |
US9555108B2 (en) | 2011-03-24 | 2017-01-31 | Texas Tech University System | TCR mimic antibodies as vascular targeting tools |
WO2012138857A2 (en) | 2011-04-08 | 2012-10-11 | Mayo Foundation For Medical Education And Research | Methods and materials for reducing supression of immune function |
EP2854845B1 (en) | 2012-06-01 | 2018-03-28 | IBC Pharmaceuticals, Inc. | Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy |
AU2013274078A1 (en) | 2012-06-14 | 2015-01-29 | Ambrx, Inc. | Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides |
US20150231241A1 (en) | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
AU2013302696B9 (en) | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
US10744129B2 (en) | 2012-12-13 | 2020-08-18 | Immunomedics, Inc. | Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 |
US10413539B2 (en) | 2012-12-13 | 2019-09-17 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
US10206918B2 (en) * | 2012-12-13 | 2019-02-19 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
BR112015013444B1 (pt) | 2012-12-13 | 2022-11-01 | Immunomedics, Inc | Uso de um imunoconjugado |
US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
EP2767549A1 (en) | 2013-02-19 | 2014-08-20 | Adienne S.A. | Anti-CD26 antibodies and uses thereof |
EP2774930A1 (en) | 2013-03-07 | 2014-09-10 | Aptenia S.R.L. | Metallocene compounds and labeled molecules comprising the same for in vivo imaging. |
CN105208855B (zh) * | 2013-03-11 | 2018-04-27 | 瑞泽恩制药公司 | 表达嵌合的主要组织相容性复合物(mhc)ii类分子的转基因小鼠 |
US9452228B2 (en) | 2013-04-01 | 2016-09-27 | Immunomedics, Inc. | Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2) |
US11253606B2 (en) | 2013-07-23 | 2022-02-22 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
CN103529202B (zh) * | 2013-09-13 | 2015-04-15 | 中国科学院合肥物质科学研究院 | 一种降低野生型人鼠杂交瘤al细胞自发突变背景的方法 |
WO2015065987A1 (en) | 2013-11-01 | 2015-05-07 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease |
ES2874884T3 (es) | 2014-02-21 | 2021-11-05 | Ecole Polytechnique Fed De Lausanne Epfl Epfl Tto | Compuestos terapéuticos dirigidos a la glucosa |
AU2015219495B2 (en) | 2014-02-21 | 2019-11-21 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
EP3110445A4 (en) | 2014-02-25 | 2017-09-27 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
SG11201608194VA (en) | 2014-04-03 | 2016-10-28 | Igm Biosciences Inc | Modified j-chain |
US10328149B2 (en) | 2014-06-13 | 2019-06-25 | Tenboron Oy | Conjugates comprising an anti-EGFR1 antibody |
US9580495B2 (en) | 2014-06-24 | 2017-02-28 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
JP7080055B2 (ja) | 2014-09-08 | 2022-06-03 | ルタナ ゲーエムベーハー | 細胞の細胞質への分子の送達のための構築物 |
SG11201707144VA (en) | 2015-03-04 | 2017-09-28 | Igm Biosciences Inc | Cd20 binding molecules and uses thereof |
WO2017185662A1 (zh) * | 2016-04-29 | 2017-11-02 | 深圳市中联生物科技开发有限公司 | 多特异性结合偶联物、相关的药物组合物及应用 |
US11000603B2 (en) | 2015-04-14 | 2021-05-11 | Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
JP6746845B2 (ja) | 2015-04-22 | 2020-08-26 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 循環trop−2陽性癌細胞の単離、検出、診断及び/または特徴付け |
JP6745873B2 (ja) * | 2015-05-22 | 2020-08-26 | ドミトリエヴィッチ ゲンキン,ドミトリー | 神経変性における治療標的としての細胞外dna |
WO2016191481A1 (en) | 2015-05-28 | 2016-12-01 | Immunomedics, Inc. | T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines |
US10195175B2 (en) | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
EP3313443B9 (en) | 2015-06-25 | 2023-10-04 | Immunomedics, Inc. | Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
EP3316885B1 (en) | 2015-07-01 | 2021-06-23 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
CA2987644A1 (en) * | 2015-08-21 | 2017-03-02 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
CA2996299C (en) | 2015-08-24 | 2022-09-27 | University Of Cincinnati | Methods and compositions for the detection of fc receptor binding activity of antibodies |
ES2883128T3 (es) | 2015-09-04 | 2021-12-07 | Health Research Inc | Anticuerpos anti-survivina para la terapia contra el cáncer |
EP3355913A1 (en) | 2015-09-30 | 2018-08-08 | IGM Biosciences A/S | Binding molecules with modified j-chain |
EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
WO2017087843A1 (en) * | 2015-11-20 | 2017-05-26 | Immungene, Inc | Methods of treating proliferative diseases using engineered antibody-interferon fusion molecules |
US20180355043A1 (en) * | 2015-12-17 | 2018-12-13 | Janssen Biotech, Inc. | Antibodies Specifically Binding HLA-DR and Their Uses |
US20170224837A1 (en) | 2016-02-10 | 2017-08-10 | Immunomedics, Inc. | Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers |
PL234632B1 (pl) * | 2016-03-02 | 2020-03-31 | Inst Immunologii I Terapii Doswiadczalnej Polskiej Akademii Nauk | Przeciwciała oddziałujące z komórkami psich chłoniaków typu B i ich zastosowania |
AU2017257254B2 (en) | 2016-04-27 | 2022-02-24 | Immunomedics, Inc. | Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors |
EP3471761A2 (en) | 2016-06-21 | 2019-04-24 | University Of Oslo | Hla binding vaccine moieties and uses thereof |
US11525009B2 (en) | 2016-06-22 | 2022-12-13 | Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. | Bispecific antibody and antibody conjugate for tumor therapy and use thereof |
CN109562172B (zh) * | 2016-08-11 | 2022-08-16 | 免疫医疗公司 | 抗HLA-DR抗体药物缀合物IMMU-140(hL243-CL2A-SN-38)在HLA-DR阳性癌症中的功效 |
AU2018240938A1 (en) | 2017-03-24 | 2019-10-10 | Zenyaku Kogyo Co., Ltd. | Anti-IgM/B cell surface antigen bispecific antibody |
US10799597B2 (en) | 2017-04-03 | 2020-10-13 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
WO2019211472A1 (en) | 2018-05-03 | 2019-11-07 | Genmab B.V. | Antibody variant combinations and uses thereof |
WO2020064847A1 (en) | 2018-09-26 | 2020-04-02 | Ascendis Pharma A/S | Degradable hyaluronic acid hydrogels |
WO2020180756A1 (en) * | 2019-03-01 | 2020-09-10 | Washington University | Compositions and methods for radiotherapy using chelated radiotherapeutic agents and non-target tissue blockade |
WO2022010797A2 (en) | 2020-07-07 | 2022-01-13 | Bionecure Therapeutics, Inc. | Novel maytansinoids as adc payloads and their use for the treatment of cancer |
WO2022008699A1 (en) | 2020-07-09 | 2022-01-13 | F. Hoffmann-La Roche Ag | Concentrated compositions of proteins, their preparation and use thereof |
CA3209479A1 (en) | 2021-02-03 | 2022-08-11 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
WO2022239720A1 (ja) | 2021-05-10 | 2022-11-17 | 公益財団法人川崎市産業振興財団 | 抗原への結合親和性を低減させた抗体 |
WO2023016488A1 (zh) | 2021-08-13 | 2023-02-16 | 昆山新蕴达生物科技有限公司 | 一种基于微管抑制剂的抗体偶联药物 |
WO2023024949A1 (zh) | 2021-08-24 | 2023-03-02 | 昆山新蕴达生物科技有限公司 | 一种由可断裂连接子偶联的抗体偶联药物 |
WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
AU2022376954A1 (en) | 2021-10-29 | 2024-05-02 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023201268A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating tumor antigen expressing cancers |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1541435A (en) | 1975-02-04 | 1979-02-28 | Searle & Co | Immunological materials |
US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US4824659A (en) | 1985-06-07 | 1989-04-25 | Immunomedics, Inc. | Antibody conjugates |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US5525338A (en) | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
US4863713A (en) | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
FR2604092B1 (fr) | 1986-09-19 | 1990-04-13 | Immunotech Sa | Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo |
US4932412A (en) | 1986-12-18 | 1990-06-12 | Immunomedics, Inc. | Intraoperative and endoscopic tumor detection and therapy |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5128119A (en) | 1989-06-12 | 1992-07-07 | Immunomedics, Inc. | Methods for technetium/rhenium labeling of f(ab1)2 fragments |
US5328679A (en) | 1988-04-01 | 1994-07-12 | Immunomedics, Inc. | Methods for technetium/rhenium labeling of proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
EP0438803B1 (en) | 1990-01-26 | 1997-03-12 | Immunomedics, Inc. | Vaccines against cancer and infectious diseases |
US5314695A (en) | 1990-11-13 | 1994-05-24 | Corvas International, Inc. | Tissue factor based prothrombin time reagent |
CA2133580A1 (en) | 1992-05-06 | 1993-11-11 | David M. Goldenberg | Intraoperative, intravascular and endoscopic tumor and lesion detection and therapy |
US6096289A (en) | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
US5792852A (en) * | 1992-11-16 | 1998-08-11 | Cancer Research Fund Of Contra Costa | Polynucleotides encoding modified antibodies with human milk fat globule specificity |
CA2151742C (en) | 1993-02-22 | 1999-05-25 | Alfred A. Amkraut | Compositions for oral delivery of active agents |
IL109666A0 (en) | 1993-05-17 | 1994-08-26 | Immunomedics Inc | A targeting composition containing a biotin- or avidinprotein conjugate and methods for the use thereof |
US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
US5443953A (en) | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
IL113610A0 (en) | 1994-06-03 | 1995-08-31 | Immunomedics Inc | A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same |
US5746996A (en) | 1994-06-03 | 1998-05-05 | Immunomedics, Inc. | Thiolation of peptides for radionuclide-based radiodetection and radiotherapy |
US8771694B2 (en) | 1994-08-12 | 2014-07-08 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells |
CA2195557C (en) | 1994-08-12 | 2006-10-17 | Shui-On Leung | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
US5798554A (en) | 1995-02-24 | 1998-08-25 | Consorzio Per La Ricerca Sulla Microelettronica Nel Mezzogiorno | MOS-technology power device integrated structure and manufacturing process thereof |
US5753206A (en) | 1995-06-07 | 1998-05-19 | Immunomedics, Inc. | Radiometal-binding analogues of luteinizing hormone releasing hormone |
AU2342897A (en) | 1996-03-20 | 1997-10-10 | Immunomedics Inc. | Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications |
CA2249320C (en) | 1996-03-20 | 2008-12-23 | Immunomedics, Inc. | Glycosylated humanized b-cell specific antibodies |
DE69737867T2 (de) | 1996-05-03 | 2007-10-18 | Immunomedics, Inc. | Zielgerichtete kombinations-immuntherapie für krebs |
DE69738353T2 (de) | 1996-07-12 | 2009-09-24 | Immunomedics, Inc. | Radiometall-bindende peptide analoge |
JP2001512438A (ja) | 1997-02-11 | 2001-08-21 | イムノメディクス,インコーポレイテッド | αガラクトシルエピトープで標識された抗体による免疫応答の刺激 |
US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
AU760854B2 (en) | 1998-06-22 | 2003-05-22 | Immunomedics Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
US6962702B2 (en) | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
US7405320B2 (en) | 1998-06-22 | 2008-07-29 | Immunomedics, Inc. | Therapeutic and diagnostic conjugates for use with multispecific antibodies |
AU5588099A (en) * | 1998-08-28 | 2000-03-21 | Dendreon Corporation | Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody |
ATE384792T1 (de) | 1998-11-18 | 2008-02-15 | Genentech Inc | Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern |
US6379698B1 (en) | 1999-04-06 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Fusogenic lipids and vesicles |
US7550143B2 (en) | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
US7666400B2 (en) | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
US7829064B2 (en) | 1999-05-10 | 2010-11-09 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods |
AU782160B2 (en) | 1999-06-09 | 2005-07-07 | Immunomedics Inc. | Immunotherapy of autoimmune disorders using antibodies which target B-cells |
US20020028178A1 (en) * | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
US6530944B2 (en) | 2000-02-08 | 2003-03-11 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
AU2001253140A1 (en) * | 2000-04-03 | 2001-10-15 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Tumor markers in ovarian cancer |
WO2003033538A1 (fr) * | 2001-10-15 | 2003-04-24 | Kirin Beer Kabushiki Kaisha | Anticorps anti-hlr-dr |
CN1604910A (zh) | 2001-10-15 | 2005-04-06 | 免疫医疗公司 | 亲和性增强物质 |
KR20050036875A (ko) | 2001-10-15 | 2005-04-20 | 이뮤노메딕스, 인코오포레이티드 | 직접 표적형의 결합 단백질 |
PL372144A1 (en) | 2001-12-26 | 2005-07-11 | Immunomedics, Inc. | Methods of generating multispecific, multivalent agents from v sb h /sb and v sb l /sb domains |
US8658773B2 (en) * | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
EP1487879B1 (en) | 2002-03-01 | 2012-12-26 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
ATE477276T1 (de) * | 2002-03-01 | 2010-08-15 | Immunomedics Inc | Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen |
US7208154B2 (en) * | 2002-06-03 | 2007-04-24 | Regents Of The University Of Michigan | Methods and compositions for the treatment of MHC-associated conditions |
EP1511518A2 (en) | 2002-06-07 | 2005-03-09 | Immunomedics, Inc. | Neutrophil imaging methods in cystic fibrosis |
WO2003104429A2 (en) * | 2002-06-10 | 2003-12-18 | Idec Pharmaceuticals Corporation | Genes overexpressed by ovarian cancer and their use in developing novel therapeutics |
US7906118B2 (en) | 2005-04-06 | 2011-03-15 | Ibc Pharmaceuticals, Inc. | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology |
AU2003277087B2 (en) | 2002-06-14 | 2008-07-31 | Immunomedics, Inc. | Humanized monoclonal antiboby hPAM4 |
EP1560596A1 (en) | 2002-11-15 | 2005-08-10 | Immunomedics, Inc. | Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics |
WO2004094613A2 (en) | 2003-04-22 | 2004-11-04 | Ibc Pharmaceuticals | Polyvalent protein complex |
ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
WO2006107617A2 (en) | 2005-04-06 | 2006-10-12 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
AU2006218454B2 (en) * | 2005-03-03 | 2011-11-17 | Immunomedics, Inc. | Humanized L243 antibodies |
JP5906743B2 (ja) * | 2012-01-05 | 2016-04-20 | ブラザー工業株式会社 | 画像形成装置 |
CN205269008U (zh) | 2013-05-06 | 2016-06-01 | 未来动力公司 | 电动交通工具、电动滑板和自平衡电动交通工具 |
FI126436B (fi) | 2013-08-23 | 2016-11-30 | Konecranes Global Oy | Käyttäjän oikeuksien hallinta nosturin yhteydessä |
KR102253091B1 (ko) | 2014-01-07 | 2021-05-17 | 삼성전자주식회사 | 기능 제어 방법 및 그 전자 장치 |
US9590284B1 (en) | 2014-05-27 | 2017-03-07 | Sandia Corporation | Self-limiting filters for band-selective interferer rejection or cognitive receiver protection |
KR20160029321A (ko) | 2014-09-05 | 2016-03-15 | 현대자동차주식회사 | 차량 내 구동모터의 진동 제어 장치 및 그 방법 |
US9382186B1 (en) | 2015-07-01 | 2016-07-05 | Celanese International Corporation | Process for producing acetic acid |
JP6187551B2 (ja) | 2015-08-28 | 2017-08-30 | コニカミノルタ株式会社 | 画像形成装置 |
JP6789667B2 (ja) | 2016-05-13 | 2020-11-25 | 日本ルメンタム株式会社 | プリント回路基板、及び光モジュール |
-
2006
- 2006-03-03 AU AU2006218454A patent/AU2006218454B2/en active Active
- 2006-03-03 DK DK18152571.8T patent/DK3332808T3/da active
- 2006-03-03 BR BRPI0607486A patent/BRPI0607486B8/pt active IP Right Grant
- 2006-03-03 EP EP06736852.2A patent/EP1853313B1/en active Active
- 2006-03-03 JP JP2007558266A patent/JP5214252B2/ja active Active
- 2006-03-03 EP EP18152571.8A patent/EP3332808B1/en active Active
- 2006-03-03 CN CN201410200592.1A patent/CN103936859A/zh active Pending
- 2006-03-03 WO PCT/US2006/007598 patent/WO2006094192A2/en active Application Filing
- 2006-03-03 US US11/368,296 patent/US7612180B2/en active Active
- 2006-03-03 CN CN200680015286.4A patent/CN101171034B/zh active Active
- 2006-03-03 ES ES18152571T patent/ES2829566T3/es active Active
- 2006-03-03 CA CA2599734A patent/CA2599734C/en active Active
- 2006-03-03 ES ES06736852.2T patent/ES2665422T3/es active Active
-
2009
- 2009-09-10 US US12/556,718 patent/US8613903B2/en active Active
-
2010
- 2010-04-05 US US12/754,140 patent/US8722047B2/en active Active
-
2013
- 2013-11-14 US US14/080,231 patent/US8992917B2/en active Active
-
2014
- 2014-03-25 US US14/224,866 patent/US9187561B2/en active Active
-
2015
- 2015-02-24 US US14/630,097 patent/US20150166659A1/en not_active Abandoned
- 2015-10-08 US US14/878,715 patent/US20160024212A1/en not_active Abandoned
-
2016
- 2016-11-16 US US15/353,141 patent/US10174114B2/en active Active
-
2018
- 2018-11-14 US US16/191,038 patent/US20190071503A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008532949A5 (ja) | ||
JP2021191763A5 (ja) | ||
JP2022031635A5 (ja) | ||
CA2529496C (en) | Anti-cd74 immunoconjugates and methods | |
HRP20191462T1 (hr) | Antitijela usmjerena protiv her-3 i njihove uporabe | |
RU2376316C2 (ru) | Человеческие антитела против человеческого 4-1вв (cd137) | |
JP2020513791A5 (ja) | ||
JP2020501531A5 (ja) | ||
HRP20170374T1 (hr) | Biološki proizvodi | |
JP2021501162A5 (ja) | ||
HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
JP2010536384A5 (ja) | ||
JP2011509245A5 (ja) | ||
JP2017535257A5 (ja) | ||
JP2022101693A5 (ja) | ||
JP2009225799A5 (ja) | ||
CA2478049A1 (en) | Humanized antibodies that recognize beta amyloid peptide | |
RU2004127458A (ru) | Анти-cd20 антитела, их гибридные белки и способы их использования | |
JP2016538318A5 (ja) | ||
JP2008542278A5 (ja) | ||
HRP20110599T1 (hr) | Antitijela protiv toksina clostridium difficile i njihove primjene | |
JP2016503067A5 (ja) | ||
JP2014529610A5 (ja) | ||
JP2017537082A5 (ja) | ||
JP2020500834A5 (ja) |